Cargando…
The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent
The colorectal cancer is the leading contributor of cancer-related mortality. Mammalian target of rapamycin (mTOR), existing in 2 complexes (mTORC1/2), is frequently dysregulated and constitutively activated in colorectal cancers. It represents an important drug target. Here we found that INK-128, t...
Autores principales: | Li, Chen, Cui, Jian-Feng, Chen, Min-Bin, Liu, Chao-Ying, Liu, Feng, Zhang, Qian-De, Zou, Jian, Lu, Pei-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623257/ https://www.ncbi.nlm.nih.gov/pubmed/25692620 http://dx.doi.org/10.4161/15384047.2014.972274 |
Ejemplares similares
-
The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
por: Zhu, Yun-Rong, et al.
Publicado: (2016) -
A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
por: Zhang, Hao, et al.
Publicado: (2013) -
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
por: Qian, Jianchang, et al.
Publicado: (2016) -
Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013) -
Exosome Release Is Regulated by mTORC1
por: Zou, Wenchong, et al.
Publicado: (2018)